Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
genentech
3
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
avapritinib
blueprint medicines
boston
deals
eli lilly
medullary thyroid cancer
non-small cell lung cancer
pralsetinib
roche
selpercatinib
thyroid cancer
acetylon pharmaceuticals
ambys medicines
cancer
cancer drugs
capmatinib
cell therapy
clinical trials
constellation pharmaceuticals
cstone pharmaceuticals
europe blog main
europe top stories
european medicines agency
fda
fisogatinib
flatiron health
gastrointestinal stromal tumors
gene therapy
hepatocellular carcinoma
holger willenbring
indiana blog main
What
medicines
3
×
approval
blueprint
cancer
drug
fda
ret
address
aiming
ambys
approves
big
biotech
candidate
carries
certain
control
currently
deadly
deal
debuted
designed
diseases
formed
future
genetic
latest
launch
liver
make
marketing
muscle
new
pact
pass
regulatory
review
roche
signature
signatures
Language
unset
Current search:
genentech
×
medicines
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
